RSS   Newsletter   Contact   Advertise with us

Cipher Pharmaceuticals appoints Robert D. Tessarolo as CEO

Staff Writer | Mississauga, ON, Canada | March 22, 2017
Cipher PharmaceuticalsMarch 22, 2017, Mississauga, ON, Canada - Cipher Pharmaceuticals, a clinical stage biotechnology company, announced that Robert D. Tessarolo has been appointed president and chief executive officer, effective April 17, 2017.
Mr. Tessarolo will also be nominated for election as a director at the Company's next annual general meeting in May 2017.

Mr. Tessarolo has 22 years of experience in the pharmaceutical industry.

He most recently held the position of Vice President & General Manager with Celgene Corporation, where he was responsible for leading their U.S. Inflammation & Immunology business.

Prior to Celgene, Mr. Tessarolo led the launch of Actavis, plc's Canadian Specialty Pharmaceutical Division and served as President and General Manager.

He established a Canadian business, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs and Allergan.

Prior to joining Actavis, Mr. Tessarolo held a number of positions of increasing responsibility with Biovail Pharmaceuticals Canada, culminating in his appointment to the position of Vice President and General Manager.

He serves on the Board of Directors of Bradmer Pharmaceuticals.

Mr. Tessarolo is a graduate of Carleton University with a B.A. in Economics and has attended the Advanced Management Program for General Management at Ross School of Business at the University of Michigan.